Sort   by:  
 Page size 
UnknownTreatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.
Not available
S-EPMC10991664 | biostudies-literature
UnknownPhase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Not available
S-EPMC7980952 | biostudies-literature
UnknownIntratumoral immunization: a new paradigm for cancer therapy.
Not available
S-EPMC3979477 | biostudies-literature
UnknownIntratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity.
Not available
S-EPMC3817012 | biostudies-literature
UnknownA microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer.
Not available
S-EPMC7167209 | biostudies-literature
UnknownImmune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade.
Not available
S-EPMC12458726 | biostudies-literature
UnknownPrimary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Not available
S-EPMC5296316 | biostudies-literature
UnknownPrime time for immune-checkpoint targeted therapy at ASCO 2015.
Not available
S-EPMC4839368 | biostudies-literature
UnknownHave lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?
Not available
S-EPMC4839322 | biostudies-literature
UnknownIntratumoural administration and tumour tissue targeting of cancer immunotherapies.
Not available
S-EPMC8130796 | biostudies-literature
Sort   by:  
 Page size